南非宫颈癌预防中不同HPV疫苗接种策略的成本效果
研究使用个体级人群模型评估南非二价与非价HPV疫苗接种策略的流行病学影响与成本效果。结果显示提高女孩接种率至90%可额外预防5%病例且节省成本,性别中立接种与接种HIV女性至45岁均具成本效果,非价疫苗每剂低于40美元时具成本效果。结论认为强化接种策略具成本效果,但单靠接种无法消除宫颈癌,需结合筛查与治疗。
要点
- 将女孩二价HPV疫苗接种覆盖率提高至90%可额外预防5%宫颈癌病例且节省成本。
- 性别中立接种80%覆盖率与仅女孩接种影响相似,每避免一个DALY成本为2782美元。
- 接种HIV女性至45岁可预防该群体10%宫颈癌病例且具成本效果。
核心结论
- 强化HPV疫苗接种策略(包括更高覆盖率、性别中立程序和针对HIV女性的接种)在南非具成本效果。
- 单一接种策略无法达到消除宫颈癌,需结合疫苗接种与宫颈癌筛查和治疗的整合措施。
研究设计与样本
- 使用个体级人群水平HPV和HIV传播模型评估南非HPV疫苗接种的流行病学影响。
- 成本基于2024年美元和来自研究获得的资源使用与价格估算。
- 计算2024年至2120年间每避免一个伤残调整生命年(DALY)的中位成本,并与机会成本阈值3015美元比较。
主要发现
- 当前干预预计到2120年将年龄标化宫颈癌发病率从每10万女性54例降至12例。
- 将仅女孩二价疫苗覆盖率提高至90%可额外预防5%病例且节省成本。
- 性别中立接种80%覆盖率影响与仅女孩接种相似,每避免一个DALY成本为2782美元。
- 接种HIV女性至45岁可预防该群体10%宫颈癌病例且保持成本效果。
- 非价疫苗每剂价格低于40美元时具成本效果。
关键数值与推荐
- 机会成本阈值为3015美元。
- 性别中立接种80%覆盖率每避免一个DALY成本为2782美元,与仅女孩接种比较。
- 非价疫苗成本效果价格阈值为每剂低于40美元。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Most cervical cancers can be prevented by population-wide vaccination of pre-adolescent girls with highly efficacious HPV vaccines. In South Africa, first-dose coverage of bivalent HPV vaccination among girls aged 10 is ∼80 %. We investigated the additional impact and cost-effectiveness of different bivalent and nonavalent vaccination strategies among the general population and women with HIV (WHIV). METHODS: We used an individual-based, population-level model for HPV and HIV transmission in South Africa to estimate the epidemiological impact of HPV vaccination. The costs of interventions in the cervical cancer care cascade are estimated in 2024 USD based on resource use and prices obtained from research studies. To estimate cost-effectiveness of different bivalent strategies, we calculated the median cost per disability adjusted life-year averted (DALY) between 2024 and 2120 and compared it to an opportunity cost (OC) threshold of USD 3015. We calculated a threshold price at which nonavalent vaccination will be cost-effective in South Africa. RESULTS: Current interventions are projected to reduce age-standardised cervical cancer incidence from 54 to 12 per 100,000 women by 2120. Increasing girl-only bivalent coverage to 90 % would prevent an additional 5 % of cases and be cost-saving. Gender-neutral vaccination at 80 % coverage would yield similar impact, with a USD/DALY averted of USD 2782 compared to girls-only vaccination. Vaccinating WHIV up to age 45 could prevent 10 % of cervical cancer cases in this group and remains cost-effective. The nonavalent vaccine would be cost-effective if priced below USD 40 per dose. CONCLUSION: Enhanced HPV vaccination strategies-including higher coverage, gender-neutral programs, and targeted vaccination of WHIV-are cost-effective in South Africa. However, no vaccination strategy alone will reach elimination, which will require integrated approaches combining vaccination with cervical cancer screening and treatment.
引用
- van Schalkwyk C, Meyer-Rath G, Masuku S, et al. Cost-effectiveness of different HPV vaccination strategies for cervical cancer prevention in South Africa. Vaccine. 2025. PMID: 40992075. doi:10.1016/j.vaccine.2025.127770
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。